Syncona-backed Achilles Therapeutics recommends voluntary liquidation, return capital to shareholders
LONDON: Syncona Ltd, a leading life science investor, announced Monday that its portfolio company, Achilles Therapeutics plc, has recommended a members’ solvent voluntary liquidation to return capital to shareholders. The decision follows a review by the Achilles Board, which determined…